Clinical outcomes
| Patient . | Best virologic response . | Post-VST course and outcome after best response . | aGVHD . | cGVHD . | Hospital days in the first 6 mo after first VST infusion, n . | ECOG status at 12 mo after transplant . | Status within follow-up period, cause of death (d after first VST infusion) . | Days of follow-up . | Long- term outcome (d after first VST infusion) . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CR | Relapsed disease | — | — | 19 | 1 | Disease relapse (69); censored at time of DLI for relapse (143) | 176 | Alive |
| 2 | CR | Well, required second VST infusion for sustained CR | — | — | 0 | 0 | Completed follow-up | 155 | Alive |
| 3 | CR | Well, sustained CR | — | Mild/limited, site unknown | 0 | 0 | Completed follow-up | 728 | Alive |
| 4 | CR | Well, required second VST infusion for sustained CR | — | — | 0 | 0 | Completed follow-up | 741 | Alive |
| 5 | CR | Well, sustained CR | — | — | 0 | 0 | Completed follow-up | 771 | Alive |
| 6 | CR | Sustained CR; admitted to hospital for severe gut, liver, and skin GVHD before and after VST infusion | Pre-infusion grade 3 (GIT); post infusion grade 4 (GIT) | Extensive (GIT, liver, skin) | 38 | 3 | Censored at enrolment in another trial (94) | 177 | Alive |
| 7 | CR | Well, sustained CR | — | — | 0 | 0 | Completed follow-up | 973 | Alive |
| 8 | CR | Admitted to hospital with CMV reactivation and pulmonary fungal infection, required second VST to achieve sustained CR | — | — | 19 | 1 | Completed follow-up | 812 | Alive |
| 9 | CR | Sustained CR; admitted to hospital for bacterial infection | — | — | 22 | 0 | Completed follow-up | 851 | Alive |
| 10 | CR | Sustained CR; admitted to hospital for fever | — | Mild/limited (skin) | 19 | 0 | Completed follow-up | 1081 | Alive |
| 11 | CR | Sustained CR; admitted to hospital for suspected sepsis; graft failure requiring second transplant | — | — | 54 | 0 | Censored at second transplant for graft failure (88) | 122 | Alive |
| 12 | CR | Well, sustained CR; relapsed disease after follow-up period | — | — | 0 | 2 | Completed follow-up | 168 | Expired, disease relapse (993) |
| 13 | PR | Complicated post-transplant course with multiple infections, bacterial sepsis, multiorgan failure, DVT, pulmonary infiltrate and pulmonary VOD; total of 4 VST infusions | — | — | 143 | 5 | Expired, pulmonary VOD (206) | 256 | Expired |
| 14 | CR | Well, sustained CR | — | — | 0 | 0 | Completed follow-up | 804 | Alive |
| 15 | CR | Well, sustained CR | — | — | 0 | 0 | Completed follow-up | 728 | Alive |
| 16 | CR | Late CMV reactivation (140 d) requiring second VST infusion, followed by sustained CR | Preinfusion grade 2 skin and GIT; postinfusion grade 2 skin and GIT | — | 15 | 1 | Completed follow-up | 499 | Expired, EBV PTLD (450) |
| 17 | CR | Well, sustained CR; admitted to hospital for Pseudomonas vulval lesions | — | — | 10 | 1 | Completed follow-up | 889 | Alive |
| 18 | CR | Well, sustained CR | — | — | 0 | 0 | Completed follow-up | 736 | Alive |
| 19 | CR | Well, sustained CR | — | — | 0 | 0 | Censored at DLI for mixed chimerism (131) | 187 | Alive |
| 20 | CR | Well, sustained CR; | — | — | 0 | 0 | Completed follow-up | 539 | Alive |
| 21 | CR | Well, sustained CR; admitted to hospital for suspected catheter-related sepsis | — | — | 8 | 0 | Completed follow-up | 419 | Alive |
| 22 | CR | Sustained CR; admitted to hospital several times for renal failure and sepsis | — | — | 77 | 5 | Expired, bacterial sepsis (122) | 179 | Expired |
| 23 | CR | Well, sustained CR; hospitalized for Clostridium difficile colitis | — | Mild/limited (skin) | 19 | 0 | Completed follow-up | 230 | Alive |
| 24 | CR | Well, required second VST infusion for sustained CR | — | — | 29 | 0 | Completed follow-up | 316 | Alive |
| 25 | CR | Well, sustained CR | Postinfusion grade 3 skin and liver | Extensive (liver, skin) | 2 | 0 | Completed follow-up | 320 | Alive |
| 26 | PR | Preinfusion BK virus hemorrhagic cystitis and cryptogenic organizing pneumonia recurring after infusion; rapid weaning from immunosuppression (steroids and cyclosporin) resulting in refractory liver GVHD | Postinfusion grade 4 GIT | — | 105 | 5 | Expired, GVHD (105) | 186 | Expired |
| 27 | CR | Well, sustained CR | — | — | 8 | 0 | Completed follow-up | 267 | Alive |
| 28 | CR | Well, sustained CR | — | — | 0 | 1 | Completed follow-up | 602 | Alive |
| 29 | CR | Well, sustained CR; admitted to hospital for diarrhea (CMV tissue disease negative) | — | Mild/limited (skin) | 5 | 1 | Completed follow-up | 258 | Alive |
| 30 | CR | Well, sustained CR; admitted to hospital with infective exacerbation of COPD | — | Mild/limited (liver, skin) | 5 | 1 | Completed follow-up | 453 | Alive |
| Patient . | Best virologic response . | Post-VST course and outcome after best response . | aGVHD . | cGVHD . | Hospital days in the first 6 mo after first VST infusion, n . | ECOG status at 12 mo after transplant . | Status within follow-up period, cause of death (d after first VST infusion) . | Days of follow-up . | Long- term outcome (d after first VST infusion) . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CR | Relapsed disease | — | — | 19 | 1 | Disease relapse (69); censored at time of DLI for relapse (143) | 176 | Alive |
| 2 | CR | Well, required second VST infusion for sustained CR | — | — | 0 | 0 | Completed follow-up | 155 | Alive |
| 3 | CR | Well, sustained CR | — | Mild/limited, site unknown | 0 | 0 | Completed follow-up | 728 | Alive |
| 4 | CR | Well, required second VST infusion for sustained CR | — | — | 0 | 0 | Completed follow-up | 741 | Alive |
| 5 | CR | Well, sustained CR | — | — | 0 | 0 | Completed follow-up | 771 | Alive |
| 6 | CR | Sustained CR; admitted to hospital for severe gut, liver, and skin GVHD before and after VST infusion | Pre-infusion grade 3 (GIT); post infusion grade 4 (GIT) | Extensive (GIT, liver, skin) | 38 | 3 | Censored at enrolment in another trial (94) | 177 | Alive |
| 7 | CR | Well, sustained CR | — | — | 0 | 0 | Completed follow-up | 973 | Alive |
| 8 | CR | Admitted to hospital with CMV reactivation and pulmonary fungal infection, required second VST to achieve sustained CR | — | — | 19 | 1 | Completed follow-up | 812 | Alive |
| 9 | CR | Sustained CR; admitted to hospital for bacterial infection | — | — | 22 | 0 | Completed follow-up | 851 | Alive |
| 10 | CR | Sustained CR; admitted to hospital for fever | — | Mild/limited (skin) | 19 | 0 | Completed follow-up | 1081 | Alive |
| 11 | CR | Sustained CR; admitted to hospital for suspected sepsis; graft failure requiring second transplant | — | — | 54 | 0 | Censored at second transplant for graft failure (88) | 122 | Alive |
| 12 | CR | Well, sustained CR; relapsed disease after follow-up period | — | — | 0 | 2 | Completed follow-up | 168 | Expired, disease relapse (993) |
| 13 | PR | Complicated post-transplant course with multiple infections, bacterial sepsis, multiorgan failure, DVT, pulmonary infiltrate and pulmonary VOD; total of 4 VST infusions | — | — | 143 | 5 | Expired, pulmonary VOD (206) | 256 | Expired |
| 14 | CR | Well, sustained CR | — | — | 0 | 0 | Completed follow-up | 804 | Alive |
| 15 | CR | Well, sustained CR | — | — | 0 | 0 | Completed follow-up | 728 | Alive |
| 16 | CR | Late CMV reactivation (140 d) requiring second VST infusion, followed by sustained CR | Preinfusion grade 2 skin and GIT; postinfusion grade 2 skin and GIT | — | 15 | 1 | Completed follow-up | 499 | Expired, EBV PTLD (450) |
| 17 | CR | Well, sustained CR; admitted to hospital for Pseudomonas vulval lesions | — | — | 10 | 1 | Completed follow-up | 889 | Alive |
| 18 | CR | Well, sustained CR | — | — | 0 | 0 | Completed follow-up | 736 | Alive |
| 19 | CR | Well, sustained CR | — | — | 0 | 0 | Censored at DLI for mixed chimerism (131) | 187 | Alive |
| 20 | CR | Well, sustained CR; | — | — | 0 | 0 | Completed follow-up | 539 | Alive |
| 21 | CR | Well, sustained CR; admitted to hospital for suspected catheter-related sepsis | — | — | 8 | 0 | Completed follow-up | 419 | Alive |
| 22 | CR | Sustained CR; admitted to hospital several times for renal failure and sepsis | — | — | 77 | 5 | Expired, bacterial sepsis (122) | 179 | Expired |
| 23 | CR | Well, sustained CR; hospitalized for Clostridium difficile colitis | — | Mild/limited (skin) | 19 | 0 | Completed follow-up | 230 | Alive |
| 24 | CR | Well, required second VST infusion for sustained CR | — | — | 29 | 0 | Completed follow-up | 316 | Alive |
| 25 | CR | Well, sustained CR | Postinfusion grade 3 skin and liver | Extensive (liver, skin) | 2 | 0 | Completed follow-up | 320 | Alive |
| 26 | PR | Preinfusion BK virus hemorrhagic cystitis and cryptogenic organizing pneumonia recurring after infusion; rapid weaning from immunosuppression (steroids and cyclosporin) resulting in refractory liver GVHD | Postinfusion grade 4 GIT | — | 105 | 5 | Expired, GVHD (105) | 186 | Expired |
| 27 | CR | Well, sustained CR | — | — | 8 | 0 | Completed follow-up | 267 | Alive |
| 28 | CR | Well, sustained CR | — | — | 0 | 1 | Completed follow-up | 602 | Alive |
| 29 | CR | Well, sustained CR; admitted to hospital for diarrhea (CMV tissue disease negative) | — | Mild/limited (skin) | 5 | 1 | Completed follow-up | 258 | Alive |
| 30 | CR | Well, sustained CR; admitted to hospital with infective exacerbation of COPD | — | Mild/limited (liver, skin) | 5 | 1 | Completed follow-up | 453 | Alive |
DLI, donor lymphocyte infusion; DVT, deep venous thrombosis; GIT, gastrointestinal; VOD, venoocclusive disease.